Phase II study of defactinib (VS6063) in patients with tumors with NF2 Loss: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol U Journal Article


Authors: Zauderer, M. G.; Jegede, O.; Jackman, D. M.; Zwiebel, J. A.; Gray, R. J.; Wang, V.; McShane, L. M.; Rubinstein, L. V.; Patton, D. R.; Williams, P. M.; Hamilton, S. R.; Takebe, N.; Huang, R.; Carrillo, J. A.; Brenner, A. J.; Tricoli, J. V.; Conley, B. A.; Arteaga, C. L.; Harris, L. N.; O'Dwyer, P. J.; Chen, A. P.; Flaherty, K. T.
Article Title: Phase II study of defactinib (VS6063) in patients with tumors with NF2 Loss: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol U
Abstract: PURPOSE The NCI-MATCH trial assigned patients with solid tumors, lymphomas, or multiple myeloma to targeted therapies on the basis of identified genetic alterations from tumor biopsies. In preclinical models, neurofibromatosis 2 (NF2)-inactivated tumors display sensitivity to focal adhesion kinase (FAK) inhibition. The EAY131-U subprotocol evaluated the efficacy of defactinib, a FAK inhibitor, in patients with NF2-altered tumors. METHODS Patients whose tumors harbored an inactivating NF2 mutation on next-generation sequencing were assigned to subprotocol U. Defactinib 400 mg was given orally twice a day until progression or intolerable toxicity. The primary end point was objective response rate (ORR), secondary end points included toxicity, progression-free survival (PFS), and 6-month PFS. RESULTS Of 5,548 patients with sufficient tissue for genomic analysis, 57 patients were found to have NF2 alterations. Thirty-five patients ultimately enrolled and 33 were treated, with one not having central confirmation and two ineligible for outcome analysis. All patients had received previous treatment, with 52% having received three or more previous lines of therapy. The most common treatment-related toxicities were fatigue (36%), nausea (33%), and hyperbilirubinemia (27%), with 27% of patients having grade 3 toxicities. Median follow-up was 35.9 months with an ORR of 3% from one partial response in a patient with choroid meningioma. Among the 12 patients (40%) with a best response of stable disease, eight demonstrated some tumor shrinkage. Median PFS was 1.9 months, and six patients achieved a PFS >5.5 months. No correlation was identified between clinical outcomes and tumor histology or specific NF2 genotype. CONCLUSION This protocol did not meet its prespecified primary end point. Defactinib monotherapy had limited clinical activity in this cohort of previously treated patients with solid tumors exhibiting NF2 loss.
Keywords: inhibitor; validation; response assessment; criteria; vs-6063
Journal Title: JCO Precision Oncology
Volume: 8
ISSN: 2473-4284
Publisher: American Society of Clinical Oncology  
Date Published: 2024-12-01
Start Page: e2400327
Language: English
ACCESSION: WOS:001382914700001
DOI: 10.1200/po.24.00327
PROVIDER: wos
PUBMED: 39693587
PMCID: PMC11803527
Notes: Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Marjorie G Zauderer
    188 Zauderer